Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

BACKGROUND: In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp1...

詳細記述

保存先:
書誌詳細
主要な著者: Revicki, Dennis A, van den Eertwegh, Alfons JM, Lorigan, Paul, Lebbe, Celeste, Linette, Gerald, Ottensmeier, Christian H, Safikhani, Shima, Messina, Marianne, Hoos, Axel, Wagner, Samuel, Kotapati, Srividya
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2012
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3426458/
https://ncbi.nlm.nih.gov/pubmed/22694829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7525-10-66
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料